Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,223,640
  • Shares Outstanding, K 254,360
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,173 M
  • EBITDA $ 4,383 M
  • 60-Month Beta 0.36
  • Price/Sales 9.23
  • Price/Cash Flow 24.79
  • Price/Book 5.92

Options Overview Details

View History
  • Implied Volatility 35.64% (-0.21%)
  • Historical Volatility 34.58%
  • IV Percentile 73%
  • IV Rank 56.13%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 4) 12.67 (2.89%)
  • Put/Call Vol Ratio 5.52
  • Today's Volume 796
  • Volume Avg (30-Day) 2,343
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 37,825
  • Open Int (30-Day) 45,550
  • Expected Range 426.06 to 451.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 33 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $3.82
  • Number of Estimates 7
  • High Estimate $4.37
  • Low Estimate $3.50
  • Prior Year $3.55
  • Growth Rate Est. (year over year) +7.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
425.26 +3.39%
on 04/07/26
463.78 -5.20%
on 03/23/26
-14.33 (-3.16%)
since 03/20/26
3-Month
425.26 +3.39%
on 04/07/26
507.92 -13.44%
on 03/10/26
-2.41 (-0.55%)
since 01/20/26
52-Week
362.50 +21.29%
on 08/11/25
510.77 -13.92%
on 04/30/25
-49.43 (-10.11%)
since 04/17/25

Most Recent Stories

More News
1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges

1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges

TPR : 153.90 (-1.25%)
VRTX : 441.79 (+0.13%)
ROK : 413.91 (-0.44%)
What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit growth in earnings.

ABT : 96.96 (+0.15%)
XLV : 148.34 (-0.31%)
$SPX : 7,110.87 (-0.21%)
VRTX : 441.79 (+0.13%)
Vertex to Announce First Quarter 2026 Financial Results on May 4th

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference...

VRTX : 441.79 (+0.13%)
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

GH : 90.61 (+0.28%)
VRTX : 441.79 (+0.13%)
OCUL : 9.51 (-3.16%)
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the...

VRTX : 441.79 (+0.13%)
1 Cash-Producing Stock with Promising Prospects and 2 We Turn Down

1 Cash-Producing Stock with Promising Prospects and 2 We Turn Down

CALY : 15.10 (-1.69%)
ARRY : 7.78 (-0.64%)
VRTX : 441.79 (+0.13%)
2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds

2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds

SYK : 342.21 (-0.32%)
VRTX : 441.79 (+0.13%)
CB : 334.62 (+1.15%)
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant

CAST : 3.27 (-6.98%)
RDZN : 1.2000 (unch)
SDST : 2.89 (-2.03%)
LTRN : 2.51 (+0.80%)
VRTX : 441.79 (+0.13%)
NRXP : 2.85 (+11.76%)
DVLT : 0.7370 (-2.77%)
SGTM : 0.2500 (-3.81%)
CISO : 0.3619 (-1.39%)
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

VRTX : 441.79 (+0.13%)
1 Momentum Stock to Research Further and 2 We Ignore

1 Momentum Stock to Research Further and 2 We Ignore

TH : 15.20 (+2.43%)
PNTG : 30.59 (-0.49%)
VRTX : 441.79 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 450.53
2nd Resistance Point 447.22
1st Resistance Point 444.21
Last Price 441.79
1st Support Level 437.89
2nd Support Level 434.57
3rd Support Level 431.56

See More

52-Week High 510.77
Fibonacci 61.8% 454.13
Last Price 441.79
Fibonacci 50% 436.64
Fibonacci 38.2% 419.14
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.